Panelists discuss how guideline-recommended treatment options for metastatic castration-sensitive prostate cancer (mCSPC) include various combinations of androgen deprivation therapy, docetaxel, and novel hormonal agents, tailored to the patient’s disease characteristics and overall health.
"Things that were typically used to recruit younger physicians need to change because those aren't their priorities anymore," says Kari Bailey, MD.
"But as you get out of expert centers and academic sites that did it for years under research protocols, the level of the quality of the reads decreases," says Jeremie Calais, MD, PhD.
Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is managed with a combination of androgen deprivation therapy, chemotherapy, and novel agents like such as abiraterone and enzalutamide, aiming to improve survival outcomes while addressing the disease's high metastatic burden.
"Honestly, there really isn't another measure of sexual quality of life for females that addresses the specific concerns of the female partners of patients with prostate cancer," says Stacy Loeb, MD, MSc, PhD (hon).
Katie S. Murray, DO, discusses why some patients do not respond to BCG therapy, exploring factors such as tumor biology and immune system dysfunction, and how this impacts their prognosis, while also addressing the challenges and unmet needs in treating these patients, including the current BCG shortages and how it is reshaping treatment approaches.
Ernest A. Morton, MD, MBA, MS, spotlights projects looking at the use of AI scribes to assist in notetaking and an AI algorithm to analyze prostate biopsies.
"It's now become one of the more popular conversations I have with people is how to use mindfulness, or at least the principles of mindfulness, in a surgical practice," says Phillip M. Pierorazio, MD.
"I'm hopeful that the decisions are more informed in terms of actual science," says Daniel Kwon, MD.
“I think as urologists, we need to become more comfortable with the female pelvic floor,” says Ava Saidian, MD.
"There's something coming out of Canada. It's a kiwi extract, which is a natural collagenase that comes from kiwi," says Landon Trost, MD.
“Before long, what we do, how we do it, and when we do it might solely be based off of those genetic testing results,” says Tim Richardson, MD.
“Time will tell as we move forward, but it has allowed us to use MDT, with or without ADT and ARPIs, to potentially look at hormone-free treatments,” says Jason M. Hafron, MD, CMO.
"I think that now we have good data that patient-reported outcomes have to be considered in these patient populations," says Andrew C. Peterson, MD, MPH.
"This year, we are starting an international rotation with a focus on global health and humanitarian work," says Akanksha Mehta, MD, MS.
"Every practice is going to be a little bit different on how they would like to approach this," says Michael Jenson, PA-C.
Panelists discuss how recent data from the EMBARK study indicates that in patients with nonmetastatic castration-sensitive prostate cancer (nmCSPC) at high risk for biochemical recurrence (BCR), enzalutamide combined with gonadotropin-releasing hormone (GnRH) significantly improves metastasis-free survival compared with monotherapy options, with no new safety signals reported.
"I joke that on face value, the APPs work for me, but I feel like I'm really working for them, because they basically do everything except for the surgery," says Andrew Y. Sun, MD.
"This has been exciting from a physician-surgeon standpoint," says Helen L. Bernie, DO, MPH.
Specifically, Jayram highlights pembrolizumab, nadofaragene firadenovec-vncg, and N-803 (Anktiva).
"Whenever they discuss germline testing, an important part of that is this pretest counseling process where you talk about the pros and the cons," says Daniel Kwon, MD.
APPs can help in introducing genetic testing and in the interpretation of results, according to Kara Cossis, PA-C, MPH.
“And you look at most of the trials that were done in this space, about 2/3 of time, over 60% of time, management was changed based on a PET scan,” says Jason Hafron, MD.
"What we found is that it's very difficult to raise your review on these websites, but fairly easy to drop your review," says Jake Miller, MD.
Katie S. Murray, DO, provides an overview of BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), defining it as a form of bladder cancer that does not respond to BCG therapy and explaining how it differs from BCG-responsive NMIBC in terms of treatment outcomes and disease progression.
“Put another way, with Apple Vision Pro, what we're hoping to do is have our residents be able to put on a headset and walk through a case before they actually walk into an operating room,” says Vikram M. Narayan, MD.
"I think what we definitively have is a device that's been around for over 50 years now that now we know significantly improves quality of life," says Andrew C. Peterson, MD, MPH.
Tim A. Richardson, MD, outlines the 2 key scenarios for utilizing genetic testing in clinical practice.
"It's often a balancing act of truly kind of pinning down people on what exactly they want to treat," says Landon Trost, MD.
